### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERO Form 4 April 09, 20	ON PHARMACE	UTICAL	S INC								
FORM									OMB AF	PROVAL	
	UNITED	STATES		RITIES A shington,			NGE C	OMMISSION	OMB Number:	3235-0287	
Check th if no long									Expires:	January 31, 2005	
subject to Section 1 Form 4 c	6. <b>SIAIEN</b>	IENT O	F CHAN	GES IN BENEFICIAL OWN SECURITIES				NERSHIP OF	Estimated average burden hours per response 0.		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type ]	Responses)										
Landry Robert E Symbol							5. Relationship of Reporting Person(s) to Issuer				
PF				REGENERON PHARMACEUTICALS INC [REGN]				(Check all applicable) Director 10% Owner			
(Last)		Middle)	3. Date of (Month/D	Earliest Transaction ay/Year)				XOfficer (give titleOther (specify below) below) SVP Finance & CFO			
777 OLD S. ROAD	AW MILL RIVE	R	04/08/2	015							
				endment, Date Original nth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
TARRYTO	WN, NY 10591							Form filed by M Person	ore than One Re	porting	
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	Securi	ties Acqu	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or				5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D)	Price	(Instr. 3 and 4)			
Common Stock	04/08/2015			M <u>(1)</u>	10,000	Α	\$ 272.7	15,000	D		
Common Stock	04/08/2015			F <u>(1)</u>	6,066	D	\$ 449.5	8,934	D		
Common Stock	04/08/2015			F <u>(1)</u>	1,835	D	\$ 449.5	7,099	D		
Common Stock								35	I	By 401(k) Plan	

#### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Non-Qualified Stock Option (right to buy)	\$ 272.7	04/08/2015		M <u>(1)</u>	10,000	(2)	09/09/2023	Common Stock	10,0

## **Reporting Owners**

Reporting Owner Name / Address	ŝ	Relationships						
	Director	10% Owner	Officer	Other				
Landry Robert E 777 OLD SAW MILL RIVER RC TARRYTOWN, NY 10591	DAD		SVP Finance &	CFO				
Signatures								
/s/**Robert E. Landry 04/09/	2015							

\*\*Signature of Reporting Person

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Date

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

(2) The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.